89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study
D. G.J. Linders*, M. M. Deken, M. A. van Dam, M. N.J.M. Wasser, E. M.C. Voormolen, J. R. Kroep, G. A.M.S. van Dongen, D. Vugts, H. M. Oosterkamp, M. E. Straver, C. J.H. van de Velde, D. Cohen, P. Dibbets-Schneider, F. H.P. van Velden, L. M. Pereira Arias-Bouda, A. L. Vahrmeijer, G. J. Liefers, L. F. de Geus-Oei, D. E. Hilling*
Research output: Contribution to journal › Article › Academic › peer-review
4Citations
(Scopus)
58Downloads
(Pure)
Fingerprint
Dive into the research topics of '89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study'. Together they form a unique fingerprint.